Exozymes Inc EXOZ

$3.83 -0.17 (-4.25%)

Valuation

Market cap
37,219,000
Revenue TTM
$0
Net income TTM
$-9,160,000
P/E (trailing)
0.00
P/E (forward)
—
Profit margin
0.00%
Debt to equity
0.00

Trading

Volume
20,000
Avg volume
10,994
Day's range
$3.54 – $4.24
Shares out
9,305,000
Stochastic %K
21%
Beta
3.34
Analysts
Hold
Price target
—

Price

Company profile

eXoZymes, Inc. operates as a development stage biotechnology company. It focuses on the development of enzyme modules and cell-free exozyme biosolutions for synthetic biology manufacturing. The company was formerly known as Invizyne Technologies, Inc. and changed its name to eXoZymes, Inc. in February 2025. eXoZymes, Inc. was incorporated in 2014 and is headquartered in Monrovia, California.

Industry
Biotechnology
Sector
Healthcare
Phone
626 415 1488
Website
https://www.exozymes.com
Address
750 Royal Oaks Drive, Suite 106, Monrovia, United States

Latest news

Stocktwits

MadMaverick Nov 13, 6:46 PM
$EXOZ follow-up 👇 Before the tech, look at the people running it. 🔹 CEO Michael Heltzen — serial biotech entrepreneur, co-founder 🔹 The science was born at UCLA — CSO Dr. Tyler Korman co-invented the platform, VP Dr. Paul Opgenorth is a cell-free engineering pioneer 🔹 Commercial chief Damien Perriman is leading the NCTx go-to-market push And the catalysts keep stacking: Curia scale-up starts Q4, the DoE Genesis Mission selection, and the annual meeting is TODAY at 1 PM PT. Technically it's basing near $4 — $4.92 is the break-and-hold to watch, $3.71 is the support to respect. If you're in, keep protection in the plan. NFA · DYODD
0 replies
MadMaverick Nov 13, 3:35 PM
$EXOZ — catalysts are stacking 👇 🔹 Curia scale-up for NCT starts Q4 2026 (Spain + Italy) 🔹 Pilot proved it: 99% yield, 99.6% purity at 100L 🔹 Selected for the DoE Genesis Mission with Berkeley Lab 🔹 ~$20M in non-dilutive funding Basing near $4. Watch the $4.92 break-and-hold; respect $3.71 support. Communicated Disclaimer - https://stockresearchtoday.com/exoz/ Other stocks moving: $FCUV $NMAX $XLAB
0 replies
MadMaverick Nov 10, 7:45 PM
$EXOZ follow-up 👇 This is where it gets interesting. eXoZymes makes rare, valuable molecules with engineered enzymes — no living cells. NCT is the first product, and what they've already proven is wild: 100× scale-up on production, 10× the productivity they originally targeted. What to look forward to: • Annual meeting this Friday, Nov 13 • Q3 update expected mid-November • Curia's commercial-scale NCT manufacturing program kicks off this quarter, with the 2027 scale-up roadmap behind it • A fresh capital raise filed last week to fund the growth push • $2M NIH grant and the DoE Genesis Mission in the background — non-dilutive support stacking up The stock is basing in the low $4S. The level that changes the conversation is still $4.92 — break and hold above it and $6.40, then $7.78, are the next stops. Support sits at $3.71. Communicated DIsclaimer - https://stockresearchtoday.com/exoz/ Other stocks moving today: $OMH $STAK $TANH $PEPG
1 replies
Cpictures Nov 9, 6:37 PM
$EXOZ Does this company actually produce anything?
1 replies
FonsieTrader Nov 9, 5:07 PM
$EXOZ just delivered a 10x productivity jump on NCT. Cell-free enzymes turning cheap feedstocks into real product — faster, cheaper, and now proven beyond original commercial targets. Manufacturing partner already locked (Curia). Tech transfer underway for commercial scale. Commercial partner next. Launch window still H1 2027. This is still a pre-revenue microcap with a tight float. When these names start moving on execution, they don’t crawl. Partners are dropping. The street is still asleep. Disclaimer: https://www.thetitanmedia.com/disclaimer/ https://exozymes.com
1 replies
FonsieTrader Nov 9, 2:31 PM
$EXOZ washed out to $3.24 on the weekly. Now $4.40 and bouncing. Earnings Thursday, Nov 12. • $40.8M cap, 7.17M float • Insiders own 65%, institutions just 1.26% • NCT showed ~10x productivity • Targeting a manufacturing partner before year-end, commercial partner after, launch H1 2027 Measured move off this base is ~+100% to $8.46. It's early: one bounce, no confirmed higher low yet. Liquidity is thin (~8.6K shares/day). Small, tightly held, binary catalysts. Disclaimer: https://www.thetitanmedia.com/disclaimer/
1 replies
MadMaverick Nov 5, 6:58 PM
$EXOZ follow-up 👇 eXoZymes is building cell-free biomanufacturing — engineered enzymes that make valuable ingredients without living cells. What to look forward to: • Annual meeting Nov 13, and the Q3 update expected mid-November — the next read on commercialization progress • The Curia commercial-scale manufacturing program for NCT starts this quarter, with the roadmap to larger-scale production in 2027 • The tech is proven at scale — NCT production already hit a 100× scale-up with near-perfect feedstock conversion, and a 10-fold productivity jump past its original commercial targets • Backing along the way: a $2M NIH grant for drug discovery and a spot in the DoE's Genesis Mission for AI-powered biomanufacturing The levels: this morning it knocked on the $4.92 level ($4.89 high) before fading to ~$4.11. Above $4.92, the next levels up are $6.40 and $7.78. Communicated disclaimer - https://stockresearchtoday.com/exoz/ $AEHL $LABT $MRNA
0 replies
Stock__Hunter Nov 3, 12:41 AM
$EXOZ Chart
0 replies